Hello, I'm Becca Parker Certified Psilocybin Facilitator Guiding Mushroom Journeys RN, CNM, FNP Learn about my deep commitment to providing a supportive, professional environment for your psilocybin journey. I share my personal background and holistic approach to being an experienced psychedelic experience facilitator, helping you to receive spiritual growth and a safe, insightful experience. A bit more about me My life’s work as a medical professional has centered in holding space for people for 50 years as a healer. This includes 50 years as a Registered Nurse and home birth midwife, 28 years as a Certified Nurse Midwife, and 25 years as a Family Nurse Practitioner and Nutritionist. I have worked at drug and alcohol rehab centers, and worked on state psychiatric wards that have enriched my training. I have childhood experiences in the war-torn environment of substance abuse, and have years of attending Alanon meetings. Continuing education is ongoing, with studies in complex trauma prominent: certification pending from the Trauma Research Foundation’s Certificate Program in Traumatic Stress Studies, under the tutelage of Bessel van der Kolk, PhD, who is a national leader in trauma therapy; and in Internal Family Systems- “No Bad Parts” with Richard Schwartz, PhD, also a national leader in trauma education). Sustaining me through the roller coaster of life is a 55-year practice of meditation that I continue to be devoted to, in conjunction with ongoing and longstanding study & practice with skilled Intuitives & Shamans. Living in Costa Rica gave me the gift of life-changing experiences with Ayahuasca, and psilocybin mushroom journeys continued with the most powerful experiences that I’ve had the privilege to experience in my life. Even at micro-doses. And even with challenging journeys. All the journeys have been taken with intentional and thorough preparation and integration that goes to the heart of the lessons offered. It is this focus and intentionality I feel I would be able to assist you with, along with holding safe & sacred space for you during journeys. It is essential that you feel safe. The time we would spend together would create that. And we would take the time that’s needed. One focus as a psilocybin facilitator is in helping people, especially women, with long-standing trauma, who would like the added confidence of working with a skilled healer and medical professional. I am happy you have found me. Eureka! The work on a psilocybin journey can be challenging, confronting, mind bending, fun, uplifting, life- changing, life-affirming, healing, life-affirming and transformative. You have a precious opportunity to make a difference in your life, with the effects rippling out into our world, at a time when we need it more than ever. With the work done during preparation and integration of your journey, I believe your life, and our world will be better off, and indeed more wonderful as a result. As we begin this journey together, there are profound possibilities, as individuals and as a connected global community. One step at a time. (In my free time I may be tango dancing, practicing yoga or Tai Chi, volunteering at SOU Plant Clinic as a Master Gardner, overseeing Kiva.org zero interest global crowdfunded loans as a Trustee, and, as a would-be musician- playing my ukulele, mandolin, guitar or piano. Last but not least- enjoying my 3 very talented and wonderful daughters and 8 grandkids. Free consultation available. All are welcome Click here for fee details and scholarships. “The Earth has a way of communicating to us through her plants. It is our duty to listen, to learn, and to heal, so that we may give back to her.” ~ Indigenous Andean Proverb

BECCA'S CURATED RESOURCES Welcome to the Resources page of Becca Parker’s website for psilocybin facilitation! Here, you'll find essential information with legal details, useful links, and access to additional research materials. Whether you're looking for legal guidance, FAQs, or further studies on psilocybin, this page offers a broad list of resources to support your journey. Explore everything from regulatory updates to expert insights, helping you stay informed and empowered throughout your experience. DISCLAIMER: All information on this website does not, & is not intended to constitute medical advice. All information, content & materials available on this site are for general informational, and educational purposes only. LEGALITIES HISTORY National Library of Medicine World History of Psilocybin Use OREGON HEALTH AUTHORITY Oregon Psilocybin Services Client Intake Forms FEDERAL U.S. Food and Drug Administration National Library of Medicine WHERE IN THE WORLD IS USE OF PSILOCYBIN LEGAL? Psilocybin is legally available in a limited number of locations, often with restrictions or under specific therapeutic guidelines. Here are the key places where it is allowed: 1. Oregon, USA: In 2020, Oregon became the first U.S. state to legalize psilocybin for therapeutic use in supervised settings. Licensed facilitators in Oregon provide guided psilocybin sessions, primarily to help with mental health conditions, although some cities in the state are considering local bans. 2. Colorado, USA: Colorado decriminalized psilocybin in 2022, allowing adults to use it for personal use and facilitating its use in controlled settings. However, retail sales remain prohibited. 3. Australia: As of 2023, Australia has legalized the medical use of psilocybin and MDMA for specific mental health conditions, including PTSD, allowing it to be prescribed by qualified psychiatrists. 4. Canada: In Alberta, psilocybin has been approved for therapeutic use in drug-assisted psychotherapy as of early 2023, though only under specific regulations. Canada also allows for the limited medical use of psilocybin in cases approved by Health Canada. 5. Countries with Decriminalized Use: Some countries, such as Brazil, Jamaica, and the Netherlands, have decriminalized psilocybin, with places like Jamaica and the Netherlands offering "psilocybin retreats" where the substance can be used in guided sessions. Other U.S. cities (e.g., Denver, Oakland, and Seattle) have also decriminalized psilocybin at the municipal level, which generally means law enforcement deprioritizes prosecuting its use but does not allow for legal sales or distribution. PORTUGAL'S DECRIMINALIZATION OF DRUGS & THE PUBLIC HEALTH IMPACT Portugal’s approach to drug policy, which involves the decriminalization of all drugs since 2001, has shown promising results for public health, particularly in reducing the mental health crisis and improving individual well-being. This policy shift reframed drug use as a health issue rather than a criminal matter. People found with small quantities of drugs face no legal penalties and are instead directed to health and social services. This reform has helped reduce the stigma surrounding drug use, encouraging individuals to seek help without fear of prosecution. Portugal’s strategy combined decriminalization with increased access to harm reduction and treatment services, such as clean needle exchanges, low-threshold methadone therapy, and expanded mental health support. This comprehensive approach has led to a decline in drug addiction rates, a drop in drug-related deaths (remaining well below the European average), and a reduction in the social costs associated with drug misuse. Overall, the approach has also improved the relationship between communities and law enforcement, as people are more likely to engage with health services instead of the criminal justice system. Recent policy updates in Portugal include decriminalizing the possession of synthetic drugs like LSD and MDMA, which has further supported harm reduction by prioritizing health over punitive measures. Experts note that this progressive stance allows for better health monitoring and even supports potential medical research on psychedelics, which could help address mental health issues by providing legal pathways for scientific exploration of their therapeutic benefits. These efforts have not increased drug use but have contributed to Portugal’s image as a model for harm reduction and mental health-focused drug policy worldwide. The outcomes support that a public health-centered approach to drug policy can effectively reduce addiction, improve mental health outcomes, and reduce the societal impacts of drug misuse. Sources: UC Berkeley Center for the Science of Psychedelics End the War on Drugs LEGALITIES Oregon Psilocybin Services Ballot Measure 109 ( now codified as ORS 475A) passed on Nov 11,2020, and it directed the Oregon Health Authority (OHA) to license and regulate the manufacturing, testing, transportation , delivery, sale and purchase of psilocybin products. oregon.gov. * Oregon Psilocybin Services (OPS) is housed within the Oregon Health Authority Public health Divisions's Center for Health Protection. To read a summary of their recent work, please see the OPS2023 Year in Review. * The National Defense Authorization Act: Legislation was passed to research the use of psilocybin to treat PTSD and Traumatic Brain Injury (TBI) in active duty service members as part of the National Defense Authorization Act (NDAA. 12-22-23 RESOURCES FOR VICTIMS OF SEXUAL VIOLENCE * National Sexual Abuse Hotline 1-800-656-4673. rainn.org Available 24 hours. * Forum- The Mighty. Themighty,com. A free online health community . Available 24/7. * Project LETS. ProjectLETS.org. Offers spaces for trauma survivors to share their stories and resources.Peer led. * Survivorsforum.womensaid.org.uk Read More > RESEARCH SAFETY Psilocybin, the active compound in certain species of psychedelic mushrooms, has been increasingly studied for its therapeutic potential and safety profile. Below are a few key scientific studies focusing on the safety and potential therapeutic applications of psilocybin: 1. Griffiths et al. (2006): Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Journal: Psychopharmacology Summary: This study assessed the safety and psychological effects of psilocybin in healthy volunteers. Participants reported significant mystical-type experiences with positive long-term psychological benefits. No severe adverse effects were reported. Conclusion: Psilocybin was found to be safe in a controlled setting, with the potential for long-lasting psychological benefits when used responsibly. Link: Griffiths et al., 2006 2. Carhart-Harris et al. (2016): Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study Journal: The Lancet Psychiatry Summary: This clinical study explored the use of psilocybin in patients with treatment-resistant depression. After receiving two doses of psilocybin, participants showed significant improvements in depressive symptoms, some lasting up to 3 months. Conclusion: The study found that psilocybin was well-tolerated with no serious adverse events, supporting its potential as a treatment for depression. Link: Carhart-Harris et al., 2016 3. Johnson et al. (2014): Safety and efficacy of psilocybin in treating anxiety in patients with advanced-stage cancer Journal: Journal of Psychopharmacology Summary: This study evaluated psilocybin’s efficacy in reducing anxiety and depression in cancer patients. Results showed significant reductions in anxiety and depression following a single dose, with effects lasting several weeks to months. Conclusion: Psilocybin was found to be safe with manageable side effects, making it a promising option for palliative care. Link: Johnson et al., 2014 4. Griffiths et al. (2018): Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal: Journal of Psychopharmacology Summary: This randomized, double-blind study assessed the effects of psilocybin on patients with life-threatening cancer. Patients experienced significant reductions in depression, anxiety, and existential distress after receiving psilocybin. Conclusion: Psilocybin was deemed safe in the short and long term, offering substantial improvements in mental health conditions related to cancer. Link: Griffiths et al., 2018 5. Nichols (2016): Psychedelics Journal: Pharmacological Reviews Summary: This review article covers the pharmacology, effects, and safety of psychedelics, including psilocybin. It highlights the low toxicity, lack of dependence potential, and the relatively safe profile of psilocybin when used in controlled environments. Conclusion: Psilocybin is considered safe for research and therapeutic use under medical supervision. Link: Nichols, 2016 6. Ross et al. (2016): Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal: Journal of Psychopharmacology Summary: This trial involved patients with life-threatening cancer who were administered psilocybin to address anxiety and depression. The results showed significant improvements in both anxiety and depression, with sustained effects. Conclusion: Psilocybin was well-tolerated and produced rapid and sustained improvements in psychological well-being. Link: Ross et al., 2016 These studies generally support the conclusion that psilocybin is safe when administered in controlled, supervised environments, with promising therapeutic potential for treating mental health conditions such as depression, anxiety, and existential distress, particularly in life-threatening situations ADDICTION WHAT WOULD BE THE IMPACT OF ALCOHOL CONSUMPTION ON A PSILOCYBIN JOURNEY? Combining alcohol with psilocybin is discouraged due to potential negative effects on both the physical and psychological aspects of a psilocybin journey. Here’s a breakdown of some potential impacts: 1. Increased Physical Risks •Dehydration: Both alcohol and psilocybin can lead to dehydration, which can increase discomfort and negatively impact the journey. •Nausea and Vomiting: Alcohol can intensify nausea, which is an occasional side effect of psilocybin. This combination may lead to vomiting, dizziness, and overall physical discomfort. •Reduced Coordination: Alcohol impairs motor skills and balance, which, when combined with the altered perception from psilocybin, can increase the risk of accidents or injuries. 2. Blunting of the Psychedelic Experience •Reduced Intensity of Effects: Alcohol can dull the psychedelic experience by interfering with the clarity and intensity of psilocybin's effects. Alcohol acts as a depressant on the central nervous system, which might counteract the heightened awareness and insights often associated with psilocybin. •Lowered Emotional Insight: Psilocybin often facilitates deep introspection, emotional openness, and self-reflection, which alcohol can diminish. Alcohol can make it more difficult to fully engage with the emotional aspects of the journey, potentially reducing therapeutic or introspective value. 3. Increased Risk of a "Bad Trip" •Anxiety and Confusion: Alcohol may increase feelings of confusion, disorientation, or even panic during a psilocybin experience. The interaction can lead to a loss of mental clarity, making it harder to process or understand the intense visual or emotional experiences that psilocybin may produce. •Negative Emotional Reactions: Alcohol can lead to emotional volatility or impulsivity, which, when paired with the profound insights or hallucinations from psilocybin, may increase the likelihood of negative emotional responses or challenging thoughts. 4. Impairment of Therapeutic Potential •Disruption of Set and Setting: Psilocybin journeys rely on a positive mindset and safe, controlled environment (often called “set and setting”) for maximum therapeutic benefit. Alcohol can disrupt this by impairing judgment, increasing impulsivity, and creating a sense of instability, which can undermine the therapeutic value of the experience. •Reduced Memory Retention: Alcohol affects memory retention, and some people report not remembering parts of the psilocybin experience if they were drinking. This can lead to a fragmented or incomplete recollection of the journey, limiting the ability to integrate insights after the experience. Summary In general, combining alcohol with psilocybin is not recommended. It can lead to increased physical discomfort, heightened emotional risk, and a reduction in the depth and clarity of the psilocybin experience. For those considering psilocybin for therapeutic or personal growth purposes, avoiding alcohol is suggested to maximize safety and the potential benefits of the journey. What would be the impact of alcohol consumption on seratonin receptors during a psilocybin journey ? Alcohol and psilocybin interact with serotonin receptors in different ways, and consuming alcohol during a psilocybin experience can interfere with psilocybin’s effects on serotonin pathways. Here’s how each substance affects serotonin receptors and what happens when they’re combined: 1. Psilocybin’s Action on Serotonin Receptors •Psilocybin primarily acts on the 5-HT2A receptors, a subtype of serotonin receptors associated with perception, mood, and cognition. When psilocybin binds to these receptors, it induces the characteristic effects of a psychedelic experience, including altered perception, emotional insights, and sometimes profound euphoria or empathy. •Psilocybin also affects 5-HT1A receptors, which can produce calming and anxiolytic effects. These effects contribute to the reflective and open mental state that psilocybin typically induces. 2. Alcohol’s Impact on Serotonin Pathways •Alcohol affects serotonin indirectly by initially increasing its release, but chronic or high doses of alcohol can lead to serotonin depletion in the brain over time. This effect is associated with alcohol’s depressant properties and its role in influencing mood and relaxation. •Alcohol doesn’t bind directly to serotonin receptors the way psilocybin does but alters serotonin signaling, which can lead to fluctuations in mood and affect mental clarity. 3. Interaction Between Alcohol and Psilocybin on Serotonin Receptors •Dampened Psychedelic Effects: Alcohol’s interference with serotonin signaling can dull psilocybin’s effects on 5-HT2A receptors, potentially blunting the clarity, emotional openness, and insights associated with a psilocybin journey. •Mood Instability: Alcohol may disrupt serotonin balance, leading to emotional volatility or mood swings during the psilocybin experience. This could heighten the risk of anxiety, confusion, or paranoia, increasing the likelihood of a challenging experience. •Reduced Neuroplasticity: Psilocybin’s effects on serotonin receptors are linked to increases in neuroplasticity, the brain’s ability to adapt and form new connections. Alcohol, especially in higher amounts, can counteract this by impairing neuronal health and plasticity, potentially diminishing the cognitive benefits typically associated with psilocybin experiences. 4. Increased Risk of Serotonin Imbalance and Serotonin Syndrome •Although rare, high levels of serotonin activation from both alcohol (in certain individuals) and psilocybin may theoretically increase the risk of serotonin syndrome, a potentially dangerous condition caused by excessive serotonin activity. This risk is more common with other serotonergic drugs, but it’s worth considering when combining any substances that influence serotonin. Summary Alcohol consumption during a psilocybin journey can interfere with psilocybin’s action on serotonin receptors, dampening the psychedelic effects and potentially causing emotional volatility and cognitive impairment. Additionally, alcohol’s indirect impact on serotonin pathways may reduce the neuroplasticity benefits associated with psilocybin, limiting its therapeutic potential. For these reasons, it’s recommended to avoid alcohol when using psilocybin to maximize safety and positive outcomes. What is the optimal clearance time between ingestion of alcohol and psilocybin? The optimal clearance time between consuming alcohol and taking psilocybin depends on factors like the amount of alcohol consumed, individual metabolism, and the desired effects of psilocybin. However, as a general guideline, it is advisable to wait at least 24 to 48 hours after drinking alcohol before taking psilocybin to ensure minimal interaction and allow your body to fully process the alcohol. Here’s why this timeframe is recommended: 1. Alcohol Clearance and Metabolism •On average, the liver metabolizes one standard drink per hour. After moderate drinking (1 The optimal clearance time between alcohol and psilocybin ingestion is generally 24 to 48 hours, depending on the amount of alcohol consumed and individual factors such as metabolism. This time frame allows for most, if not all, of the alcohol to be processed by the body and reduces the likelihood of adverse interactions. Here’s a breakdown of why this is important: 1. Metabolism of Alcohol •The liver typically metabolizes one standard drink per hour, but this rate can vary. After drinking more than 2–3 standard drinks, it may take up to 12 hours or more for your body to eliminate all alcohol from your bloodstream. •For moderate or heavy drinking, waiting a full 24 hours is ideal. After binge drinking, a 48-hour window is safer to ensure no residual effects from alcohol remain. 2. Mental and Emotional State •Alcohol can impair judgment, mood stability, and cognitive function. Allowing at least 24 hours gives your brain and body time to recover fully from these effects, which is essential for an optimal psilocybin experience, as psilocybin requires a clear and stable mental state. 3. Avoiding Potential Physical and Chemical Interactions •Alcohol can interfere with the serotonin system and nervous system activity, potentially impacting psilocybin's effects. Waiting 24 to 48 hours helps prevent any residual alcohol from altering psilocybin's interaction with serotonin receptors. Summary For a safe and effective psilocybin experience, a 24- to 48-hour clearance period after drinking alcohol is recommended. This allows for physical recovery, mental clarity, and the reduction of any potential interactions between alcohol and psilocybin SELF EXPLORATION A psilocybin journey can be a powerful tool for self-exploration by promoting deeper introspection and emotional release. A psilocybin journey facilitated by a trained facilitator often allows for a more profound connection to oneself, leading to insights into personal challenges, relationships, or life direction. With the right mindset and preparation, and by integrating these insights afterward, people can use psilocybin to foster emotional healing, spiritual growth, and self-discovery. END OF LIFE END OF LIFE PSYCHEDELIC CARE EOLPC.org Their mission is to create the environment where the safe use of psychedelic medicine is accessible and affordable for anyone faced with a life-threatening illness. End of Life Choices.org One of the choices is through a program called "Delivering Oneself" for those who do not meet the requirements for Death With Dignity. (Those qualifications are to be an OR resident, 21 years of age or older, have a terminal diagnosis with 6 months of life to live or less, and can self-administer the 4 drugs utilized. "Delivering Oneself" is a legal program. WHEN DEEPER AND MORE EXTENSIVE WORK IS NEEDED When deeper or more extensive work is needed or wanted to heal trauma- Journey to Completion http://www.journeytocompletion.com/ offers an advanced process that combines psycho-therapeutic techniques with Jungian Depth Psychology to address "Shadow Work" Integration. It follows a powerful ancient pathway through the unconscious to break cycles of pain and retrieve creativity, then leads you back home to a deeper, more complete sense of self. Led by Norma Burton, who has studied with wisdom keepers around the world, the process blends sacred knowledge from the North, East, South, and West- the sacred four directions. Norma holds a M. Div in Psychology of Religion, MS, PhD, Graduate Theological Union, Berkeley, in Comparative Religions, Post Graduate studies in Somatic Psychology at SBGI. journeytocompletion.com. CREATIVITY RESEARCH STUDIES ON THE USE OF PSILOCYBIN FOR CREATIVITY ChatGPT said: Research on psilocybin’s effects on creativity is relatively new, but several studies indicate that it may enhance creative thinking by altering brain activity and perception. Here are some notable studies and their findings: 1. Maastricht University – Effects of Microdosing on Creativity •Study: “Exploring the Acute and Long-Term Effects of Psilocybin on Creativity” •Reference: Prochazkova, L., et al. (2018). Psychopharmacology, 235(12), 3401-3413. •Findings: This study investigated the effects of microdosing psilocybin on divergent and convergent thinking, both of which are key components of creativity. Divergent thinking is associated with generating multiple solutions, while convergent thinking focuses on narrowing down to a single solution. Researchers found that microdosing psilocybin improved divergent thinking, suggesting enhanced originality and flexibility in thought. Convergent thinking was unaffected, suggesting that microdosing may support creative ideation without impairing problem-solving focus. 2. Imperial College London – Brain Connectivity and Creativity •Study: “Increased Brain Connectivity under Psilocybin and the Associated Boost in Creativity” •Reference: Carhart-Harris, R. L., et al. (2014). Proceedings of the National Academy of Sciences, 111(23), 8874-8879. •Findings: Researchers used fMRI to study psilocybin’s effects on brain connectivity and found that it temporarily enhances connectivity between different brain regions, particularly in the default mode network (DMN). Increased connectivity may lead to more fluid and flexible thought processes, allowing for new ideas and perspectives, which are crucial to creative thinking. Participants also reported a heightened sense of openness and emotional sensitivity, which are often associated with creativity. 3. University of Leiden – Microdosing and Creative Problem Solving •Study: “Psychedelic Microdosing and Enhancement of Creative Problem Solving” •Reference: Kuypers, K. P. C., et al. (2016). Frontiers in Psychology, 7, 1472. •Findings: This study focused on the effects of microdosing on creativity in a controlled setting. It found that psilocybin microdoses improved participants’ ability to think outside the box, particularly on tasks requiring unconventional solutions. Participants reported feeling more open-minded and less bound to rigid thought patterns, which enhanced their problem-solving abilities. These results suggest that even low doses of psilocybin may enhance creativity by enabling more flexible thinking. 4. University of California, Davis – Psilocybin’s Effect on Openness and Creative Thinking •Study: “Psilocybin-Induced Changes in Personality and Implications for Creativity” •Reference: MacLean, K. A., et al. (2011). Journal of Psychopharmacology, 25(11), 1453-1461. •Findings: This longitudinal study observed that a single high-dose psilocybin session led to lasting increases in “openness,” a personality trait associated with creativity, curiosity, and imagination. Notably, these changes in openness persisted for over a year in many participants, suggesting that psilocybin may have long-term impacts on creative thinking by fostering openness to new ideas and experiences. 5. Experimental Studies on Flow States and Creativity •Study: “Exploring the Effects of Psychedelics on Flow and Creative Output” •Reference: Barrett, F. S., et al. (2020). Frontiers in Psychology, 11, 575509. •Findings: This study explored the relationship between psilocybin, flow states, and creativity. Psilocybin was found to increase the likelihood of experiencing flow—a mental state of deep immersion and focus, which is often linked to peak creative performance. Enhanced flow states can lead to more productive creative output and a stronger connection to the creative process, suggesting that psilocybin might facilitate both artistic and problem-solving creativity. Mechanisms Behind Psilocybin’s Effect on Creativity Several mechanisms have been proposed for psilocybin’s effects on creativity: •Enhanced Brain Connectivity: Psilocybin increases connectivity across different brain regions, promoting novel connections and associative thinking, both of which are critical to creative thought. •Reduced Default Mode Network Activity: Psilocybin reduces DMN activity, allowing people to think beyond self-referential or habitual patterns, potentially leading to more expansive and novel ideas. •Increased Openness: By enhancing openness, psilocybin helps individuals explore ideas they might otherwise dismiss, encouraging curiosity and innovative thinking. Summary Although research is in its early stages, studies indicate that psilocybin may enhance creativity by promoting flexible thinking, increasing openness, and enhancing the brain’s ability to form new connections. Further research is needed to establish standardized protocols, understand the optimal dosages, and explore the potential applications for creativity in professional and artistic contexts. TRAUMA WHAT ARE THE STUDIES ON THE USE OF PSILOCYBIN FOR TRAUMA? Psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, has garnered significant interest in recent years for its potential therapeutic applications, including the treatment of trauma-related conditions such as Post-Traumatic Stress Disorder (PTSD). While much of the research on psilocybin has focused on its efficacy in treating depression, anxiety, and addiction, emerging studies suggest promising avenues for its use in addressing trauma. Below is an overview of key scientific studies and findings related to the use of psilocybin for trauma: 1. Psilocybin and Emotional Processing in Trauma Study: Carhart-Harris et al. (2016) Title: "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study" Findings: While primarily focused on depression, this study highlighted psilocybin's ability to enhance emotional processing and reduce rumination, which are critical factors in trauma recovery. Participants reported significant improvements in mood and emotional flexibility, suggesting potential benefits for trauma-related emotional dysregulation. 2. Psilocybin-Assisted Therapy for PTSD Study: Garcia-Romeu et al. (2019) Title: "Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction" Relevance to Trauma: Although centered on addiction, the study demonstrated that psilocybin-assisted therapy could induce profound psychological experiences that facilitate behavioral change. These mechanisms are relevant for trauma treatment, where altering entrenched patterns of thought and behavior is essential. 3. Mechanisms of Action Relevant to Trauma Treatment Research Overview: Studies have explored how psilocybin interacts with the brain's serotonin receptors, particularly the 5-HT2A receptor, leading to increased neuroplasticity and connectivity between different brain regions. This enhanced connectivity may allow individuals to reprocess traumatic memories and integrate them in a healthier manner. Additionally, psilocybin-induced mystical experiences can foster a sense of interconnectedness and reduce fear responses, which are beneficial in trauma therapy. 4. Clinical Trials and Ongoing Research Ongoing Study: Institution: Johns Hopkins Center for Psychedelic and Consciousness Research Focus: Investigating the efficacy of psilocybin-assisted therapy in various mental health conditions, including trauma-related disorders. Preliminary results indicate that psilocybin can reduce symptoms of anxiety and depression in individuals with trauma histories, though specific studies on PTSD are still in progress. Ongoing Study: Institution: Imperial College London Focus: Exploring the potential of psilocybin to enhance psychotherapy for PTSD by facilitating emotional breakthroughs and reducing avoidance behaviors. 5. Systematic Reviews and Meta-Analyses Review: Pollan et al. (2022) Title: "Psychedelics and Mental Health: A Review of Current Evidence" Findings: This review synthesized data from multiple studies, concluding that psychedelics like psilocybin show promise in treating various mental health conditions, including those related to trauma. The authors call for more targeted research to fully understand psilocybin's efficacy and safety in trauma populations. 6. Safety and Ethical Considerations Study: Johnson et al. (2008) Title: "Human hallucinogen research: guidelines for safety" Findings: Emphasizes the importance of controlled environments and professional guidance when using psilocybin therapeutically, especially for individuals with trauma histories who may be more susceptible to adverse psychological reactions. Conclusion and Future Directions While the body of research specifically targeting psilocybin's use in trauma treatment is still developing, existing studies provide a foundational understanding of its potential benefits. Psilocybin-assisted therapy may offer a novel approach to trauma by facilitating emotional processing, enhancing neuroplasticity, and promoting psychological insights. However, more rigorous, trauma-focused clinical trials are necessary to establish efficacy, optimal dosing protocols, and safety profiles. Key Considerations for Future Research: Population Specificity: Focusing on individuals diagnosed with PTSD or complex trauma. Longitudinal Studies: Assessing the long-term effects of psilocybin-assisted therapy on trauma symptoms. Integration with Psychotherapy: Exploring how psilocybin can be effectively combined with existing therapeutic modalities for trauma. Safety Protocols: Ensuring robust safety measures to support individuals during and after psilocybin experiences. As regulatory landscapes evolve and the stigma surrounding psychedelics diminishes, it is anticipated that research on psilocybin for trauma will expand, potentially offering new hope for individuals struggling with the enduring impacts of traumatic experiences. MORE RESOURCES Organizations *DecriminalizeNature.org. A grassroots organization advocating for the decriminalization of entheogenic plants. *UC Berkeley Center for the Science of Psychedelics * End the War on Drugs. (The war on drugs is widely reviewed as a policy failure). www.aclu.org. NAACP.org for an Exit Strategy to end the war on drugs. Johns Hopkins Center for Psychedelics and Consciousness Research hopkinspsychedelic.org. The center focuses on conducting research studies on psychedelics, which includes studying the potential therapeutic benefits and efficacy of psychedelics. Their vision is to advance the scientific understanding of psychedelics and their potential for treating mental health. Coyote-Institute.org. A 501c3 that aims toward "Two-Eyed Seeing", bringing the wisdom of indigenous peoples to the modern world. "The coyote is our muse, because coyote is a powerful North American symbol for change and transformation. Coyote's job is to intervene when any system gets too rigid and inflexible, providing input to move the leading Read More > AMAZING RESOURCES RECOMMENDED BOOKS: I have listed 6 books here that I feel would prepare you well emotionally for your psilocybin journey. Please seriously consider reading them. * No Bad Parts. Richard Schwartz, PhD. 2021. Dr Schwartz is the creator of Internal Family Systems, a highly effective, evidence-based therapeutic model that addresses "our inner critics", the "monkey mind" with an approach that ends a constant inner struggle. It is an excellent tool in working with the critic, the sabatour, guilt & shame and is an astounding tool for preparatory work and integration of a psilocybin journey. * The Body Keeps the Score. Bessel van der Kolk, MD. 2014. A pioneering & lead researcher who has transformed our understanding of trauma and offers a bold paradigm for healing. It offers understanding about trauma that is imperative to healing. * Workbook: The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. Liam Daniels, 2023 * What Happened to You? Conversations on Trauma, Resilience & Healing. Bruce Perry, child psychiatrist, MD & Oprah Winfrey. Shifts the conversation from "what's wrong with you to what happened to you? * LSD & the Mind of the Universe: Diamonds from Heaven. Christopher Bache, PhD. 2019. Bache chronicles his 73 LSD journeys over the course of 20 years to deepen and understand his communion with cosmic consciousness. * The Courage to Heal: A Guide for Women. Ellen Bass & Laura Davis.1988. Best selling self help book for survivors of incest. WORTHY DOCUMENTARIES AND MOVIES 1) Fantastic Fungi : How Mushrooms can Heal, Shift Consciousness & Save the Planet. Paul Stamets The Way of the Psychonaut. Explores the life and work of Stanislav Grof, psychiatrist & psychedelic psychotherapy pioneer. Podcast: Adventures Through The Mind. You Tube. A Psychedelic Podcast hosted by author, Jamew W Jesso. This audio & video podcast presents long-form, unedited conversations with various experts. International Center for Ethnobotanical Education Research and Service (ICEERS). ICEERS is a non profit dedicated to navigate the challenges of the globalization of traditional indigenous medicines. The Psychedelic Pharmacists Association (PPA) psychedelicpharmacist.org The leading non-profit devoted to pharmacists advancing psychedelics as medicines. They advocate education about the therapeutic use of psilocybin medicines and their place in the continuum of care. Recommended Books: * No Bad Parts. Richard Schwartz, PhD. 2021. Dr Schwartz is the creator of Internal Family Systems, a highly effective, evidence-based therapeutic model that addresses "our inner critics", the "monkey mind" with an approach that ends a constant inner struggle. It is an excellent tool in working with the critic, the sabatour, guilt & shame and is an astounding tool for preparatory work and integration of a psilocybin journey. * The Body Keeps the Score. Bessel van der Kolk, MD. 2014. A pioneering & lead researcher who has transformed our understanding of trauma and offers a bold paradigm for healing. It offers understanding about trauma that is imperative to healing. * Workbook: The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. Liam Daniels, 2023 * The Courage to Heal: A Guide for Women. Ellen Bass & Laura Davis.1988. Best selling self help book for survivors of incest. * What Happened to You? Conversations on Trauma, Resilience & Healing. Bruce Perry, child psychiatrist, MD & Oprah Winfrey. Shifts the conversation from "what's wrong with you to what happened to you? * LSD & the Mind of the Universe: Diamonds from Heaven. Christopher Bache, PhD. 2019. Bache chronicles his 73 LSD journeys over the course of 20 years to deepen and understand his communion with cosmic consciousness. Johns Hopkins Center for Psychedelics and Consciousness Research hopkinspsychedelic.org. The center focuses on conducting research studies on psychedelics, which includes studying the potential therapeutic benefits and efficacy of psychedelics. Their vision is to advance the scientific understanding of psychedelics and their potential for treating mental health. Coyote-Institute.org. A 501c3 that aims toward "Two-Eyed Seeing", bringing the wisdom of indigenous peoples to the modern world. "The coyote is our muse, because coyote is a powerful North American symbol for change and transformation. Coyote's job is to intervene when any system gets too rigid and inflexible, providing input to move the leading non profit system toward transformation and change. Erowid Center. www.erowid.org. The Erowid Center, a non profit educational organization that provides information about psychoactive plants and chemicals. Erovid has documented legal- and illegal- substances, including their intended and adverse effects- by thousands of participants. This link is presented for free access to information and ideas. The FAX page is an attempt to prepare 1st time users of psychoactive substances. One may refer to Erowid's summary pages in the substances main vault. The Hakomi Institute hakomiinstitute.com. Hakomi combines advances in neuroscience with the gentle inward-looking practice of Mindfulness. Conferences Coyote Institute. Two-Eyed Seeing. Jan 26-28, 2025. Online & in Maine. Psychedelic Science.org. June 16-20, 2025 MAPS sponsored conference, Denver, Colo. Zendo Project www.firesideproject.org. A non-profit founded in 2022 by mental health professionals and supported by a team of volunteers that includes doctors, psychedelic therapists, nurses, social workers, healing facilitators and harm reduction experts. Incubated for 10 years at MAPS, they provide free integration support and support during psychedelic experiences. They provide free education & psychedelic peer support services to organizations and communities. NOTE WORTHY ORGANIZATIONS Erowid Center. www.erowid.org. The Erowid Center, a non profit educational organization that provides information about psychoactive plants and chemicals. Erovid has documented legal- and illegal- substances, including their intended and adverse effects- by thousands of participants. This link is presented for free access to information and ideas. The FAX page is an attempt to prepare 1st time users of psychoactive substances. One may refer to Erowid's summary pages in the substances main vault. The Hakomi Institute hakomiinstitute.com. Hakomi combines advances in neuroscience with the gentle inward-looking practice of Mindfulness. CONFEERENCES Coyote Institute. Two-Eyed Seeing. Jan 26-28, 2025. Online & in Maine. Psychedelic Science.org. June 16-20, 2025 MAPS sponsored conference, Denver, Colo. Horizons: Perspectives on Psychedelics. An annual conference that covers cutting edge psilocybin research. horizonspbc.com Participating in conferences that discuss the therapeutic potential and safe use of psychedelics can open up dialogue. These events often feature experts from various fields such as psychiatry, neuroscience and anthropology. ORGANIZATIONS Zendo Project www.firesideproject.org. A non-profit founded in 2022 by mental health professionals and supported by a team of volunteers that includes doctors, psychedelic therapists, nurses, social workers, healing facilitators and harm reduction experts. Incubated for 10 years at MAPS, they provide free integration support and support during psychedelic experiences. They provide free education & psychedelic peer support services to organizations and communities. need, while keeping your layout clean. Read More > “Psychedelics may not only provide healing from the psychological conditions we classify as mental illness, but may also offer something more existentially essential: relief from our habitualized way of seeing and being in the world.” ~Michael Pollan, author of How to Change Your Mind

THE HISTORY OF PSILOCYBIN USE The history of psilocybin use spans thousands of years, intersecting with indigenous practices, scientific research, countercultural movements, and modern politics. Here's an overview: Ancient and Indigenous Use · 7-9 K years ago: The earliest evidence of psychedelics is in a cave in the Tassili-N-Ajjer region of the Sahara Desert, Algeria- on a mural. The mural depicts “mushroom man” or “mushroom shaman”, a bee-headed figure with mushrooms sprouting out of his body. Identified as PSILOCYBE MAIREI, which were native to the region. · 6 K years ago: The Selva Pascuala mural in a cave near Villar del Humo, Spain. It features mushrooms researchers believe to be PSILOCYBE HISPANICA, a local species · 5,700 years ago The identification of mescaline strengthened the evidence that native North Americans recognized the psychotropic properties of peyote as long ago as 5,700 · 5000 BC- Psychedelics used in Central America; Ayahuasca used in the Amazon; Iboga used in West Africa · 3700 BC. Evidence of the use of PEYOTE ( a cactus containing the psilocybin MESCALINE) in the Rio Grande, Texas. · Brian Muraresku (The Immortality Key: The Secret History of The Religion With No Name, delineates 12 years’ worth of research and data revealing ritualistic psychedelic use in classical antiquity- among ancient Greeks, Romans & Paleo Christians. Psychedelic wine was drunk outside Pompei from the 1st century AD- the same time early Christians were there. This is revolutionary. This subject is discussed in The Mystery Religion of ancient Greece- the Eleusian Mysteries. Implications for Christianity are far reaching. · There was ritual use of psychedelic beer in Iberia · 392 BC, Greece – psychedelic use was wiped out by the Catholic Church · 3K plus years ago in Peru, the use of the San Pedro cactus (which also contains mescaline) was known · 1300 BC in N Peru, a stone carving of a deity shows the god holding the San Pedro cactus · 1K-1500K BC mushroom stones were found in both Mexico and Guatemala, indicating the use of psilocybin mushrooms · 15th century Spanish missionaries attempted to destroy all records and evidence of the use of these mushrooms, · 16th + 17th century Spanish conquistadors in Central & South America were appalled that the people utilized plants, and that women were involved. It was threatening as psychedelics gave power to the people. During the inquisition, lasting more than 350 years- between 1478 & 1834- using plants was punishable by death. Nevertheless, a 16th century Spanish Franciscan friar and historian mentioned TEONANACATL in his extensive writings, intriguing 20th century ethnopharmacologists and leading to a decades long search for the identification of TEONANACATL. · South American Aztec Indians referred to magic mushrooms as TEONANACATL, meaning God’s flesh, and they were used in religious and healing rituals. · 1K years ago, a study published in the Proceedings of the National Academy of Sciences described the discovery of a shaman’s pouch in SW Bolivia, containing multiple psychedelics, including BUFOTENIN and DMT. Interestingly, the pouch contained HARMINE which can be combined with DMT to potentiate psilocybin effects. (DMT is both a derivative and a structural analog of tryptamines. Half life 9-12 minutes. Administration: by mouth with a MAOI), vapor, insufflation, rectal, IM, IV) · 1K years ago. The researcher Dennis McKenna points out there isn’t data showing exactly how far back Ayahuasca use dates- but undoubtedly thousands of years · 1895 saw the 1st scientific trial involving peyote in Wash, DC @ Columbia Univ (now George Washington Univ). · 1897 German Pharmacist Arthur Heffter consumed 150 mg mescaline that he had isolated. This was the 1st experience with a purified psychedelic · 1904 Mycologist Franklin Earle was the 1st person to identify Psilocybe Cubenis in Cuba · 1912 German chemist Anton Kottisch - 1st to synthesize MDMA · 1919 Austrian chemist Ernst Spath- 1st to synthesize mescaline * 1930s-1950s: Western anthropologists and ethnobotanists, such as Richard Evans Schultes, documented indigenous mushroom ceremonies. R. Gordon Wasson's famous 1957 Life magazine article introduced psilocybin to mainstream Western audiences. · 1931 Canadian chemist Richard Manski - 1st to synthesize DMT · 1938 Swiss chemist Albert Hofman, who worked for Sandoz Pharmaceuticals, developed LSD from ergot that grows on wheat and barley. LSD-25 was the 25th variation. He did not realize it’s capabilities. · 1943 he had a peculiar “presentiment” that there was something worthwhile in it. He accidentally ingested some on his finger and had an unexpected experience. A few days later he planned an experiment with it. He ingested 250 micrograms of LSD, which he thought would represent a prudently safe, small amount, but was in fact a strong dose. He had a period of psychosis with it. Sandoz Pharmaceuticals sent free packets of LSD to any chemist who wanted to research it. · 1946 Microbiologist Oswaldo Goncalves de Lima discovered DMT’s natural occurrence in plants (Goncalves de Lima, 1946) · 1949 The psychiatrist Max Rinkel carried out the 1stexperiment in the US by giving 100 volunteers at the Boston Psychopathic Institute. He believed the effects of the drug mimicked schizophrenic psychosis- calling LSD a “madness mimicking” agent Throughout the 1950s, over 500 articles on LSD appeared in scientific journals. Post WW2 era doctors and psychiatrists explored LSD for its potential therapeutic value. Doctors had free reign in the 50’s and 60’s to study psychedelics. This was the “1st wave” of research in the US, and also in Europe. 1958: Albert Hofmann, the Swiss chemist who discovered LSD, first synthesized psilocybin from Psilocybe Mexicana mushrooms. There were also CIA funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Some of the most wide-spread trials in the Western World occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Haffer (in Saskatoon). Far from being fringe medical research, these LSD trials represented a fruitful, and encouraging, branch of psychiatric research occurring alongside more famous and successful trials of the 1st generation of psychopharmacological agents, such as chlorpromazine and imipramine. Ultimately, these LSD experiments failed for 2 reasons, one scientific and the other cultural. First, in the 1950s and early 1960s, the scientific parameters of clinical trials shifted to necessitate randomized controlled trials, which the Saskatchewan researchers had failed to construct. Second, as LSD became increasingly associated with student riots, antiwar demonstrations, and the counterculture, governments intervened to criminalize the drug, restricting and then terminating formal medical research into its potential therapeutic effects (Can J Psychiatry June 2005; Vol 50, No 7:381-388) (article Flashback: Psychiatric Experimentation with LSD in Historical Perspective. Erika Dyck. 2005 · 1950-1965- 40,000 patients were given psychedelic drugs in trials researching the schizophrenic process. This resulted in over 1000 scientific papers. · 1952 American Charles Savage published 1st study looking at LSD as a treatment for depression in the American Journal of Psychiatry. Results were inconclusive, meaning it made no difference in outcomes. · 1952 Humphry Osmond published studies on LSD use for treating those with alcohol abuse. He was at the cutting edge of psilocybin research. It led to his association with novelist Aldous Huxley, who after receiving psychedelics, wrote Doors of Perception. His research also led to his involvement with the CIA and M16, which were interested in LSD as a possible “truth drug” to make enemy agents reveal secrets. · 1955 Gordon Wasson, then vice president of JP Morgan in NYC, is told by a friend of magic mushrooms & goes to Mexico in search of someone who would lead him in a psilocybin ceremonies. Maria Sabina took him under her wing for 2 years. After which time, and against Maria’s wishes to keep her photo and information private about her life & the sacred ceremonies he had learned of and participated in, he recounted his experiences in Life Magazine. It was on the front page of the most widely read magazine in America at the time- 1957.Wasson was also followed to Mexico by the CIA, due to their interest in psychedelics.0 · 1956 Czech psychiatrist Stanislas Grof had his 1st experience with LSD, ingesting 250 micrograms. He went on to pioneer the use of Holotropic Breathwork and Transpersonal Psychology. Grof carried out more than 4,000 LSD assisted therapy sessions, many at Esalen Institute where he led group workshops for decades. He had a tremendous influence in the US, more than any other researcher, in adding to scientific study and knowledge and creating a socially acceptable cultural milieu that helped prove the therapeutic value of psychedelics. He said that transformation belongs to the psyche of the person- NOT the medicine. One of his books is called The Way of the Psyche. He stated that the psyched has the inclination to reintegrate itself, but if integration is not complete- “use body work to areas that are off”. He and his wife are currently doing trainings coupled with breathwork. · 1956 Hungarian chemist & psychiatrist Stephen Szara- extracted DMT from the MIMOSA HOSTILIS plant and administered the extract to himself intramuscularly. This, along with Manske’s He made major contributions in the field of pharmacology. DMT’s natural occurrence in plants, formed the link between modern science and the historical use of many DMT-containing plants as a cultural and religious ritual sacrament (McKenna et al, 1998), their effect on the psyche and the chemical structure of DMT. He was the 1st person to describe its psychedelic effects. He moved to the US after the Hungarian Revolution and eventually became Chief of the Biomedical Branch of the US National Institute on Drug Abuse. He worked on the metabolism of DMT in healthy and schizophrenic volunteers. · 1957 front page, Life Magazine - titled SEEKING THE MAGIC MUSHROOM, about Gordon Wasson’s experiences in Mexico. The Life article resulted in hundreds swarming to Mexico, overrunning the town she lived in, changing the culture and turning the local and national people against her. Her home was burned down 1960 twice. She died in poverty. · 1960 Timothy Leary, took mushrooms in Mexico before he arrived at Harvard to teach (inspired to go through Gordon Watson’s Life magazine article. He said he “learned more in 5 hours utilizing the mushrooms than he had from 15 years of study”. He was an enigmatic prominent researcher at Harvard university. On return to Harvard, he received permission to study psychedelics. That was the beginning of the Harvard Psychedelic Research Project where 20 theological students participated. 8 received psychedelics. 9 had mystical experiences. He was fired, along with Richard Alpert (who renamed himself Ram Das, and wrote “Be Here Now”) in 1963 for his controversial practice of taking psilocybin along with his subjects. With his charismatic personality and Irish back ground he took to the streets to become a crusader for psilocybin use. He was arrested 36 times. He was known for a 8-circuit model of consciousness He was famous for “Turn on, tune in, drop out.” · On the west coast Ken Keasey trumpeted psilocybin. Loudly. Early Researchers: Albert Hofmann- Discovered LSD Huston Smith- religious scholar. He said “in the end, it’s altered traits that matter- not altered states”. He was a member of the 1998 Elders Council. He received the 2010 APPPAH award Richard Alpert- Harvard teacher & psilocybin researcher. He became RAM DAS, writing BE HERE NOW in 1971 Ralph Metzer, PhD. German born American psychologist & writer. Metzner & Ram DAS wrote Birth of a Psychedelic Culture. He founded the Green Earth Foundation. Gabor Mate, Hungarian – Canadian Physician and prolific author. Expert in childhood trauma & it’s impacts on physical and mental health, including autoimmune disease, cancer, ADHD, addictions. His research informs mental health today. He is known for his book “in the Realm of Hungry Ghosts: Close Encounters with Addiction. His most recent book is The Myth of Normal. 1960’s- Psychedelics eventually made their way to the streets as Timothy Leary became an apostle for liberation. · Underground chemists, such as Leonard Pickard, Nick Sand & Owsley Stanley, started to manufacture the inexpensive LSD and distribute them to the general public. They produced millions of doses. It was when psychedelics entered the public realm and popular culture that the law surrounding their production, sale and possession started to change. It was the time of the Vietnam War, and the protesters of the war were associated with protests, riots, rebellion, radicalism. · White Bird in SF starts harm reduction efforts 1965- Willis Harman, Stanford professor, later to become president of the Institute of Noetic Sciences, and Robert Mogar, Associate Professor of Psychology, San Francisco State College, gained the agreement of the Administration of SF State College to set up The Institute of Psychedelic Research. Harman wondered if psylocibin could focus the mind for scientific problem solving, not mysticism or psychotherapy. Unfortunately, the turmoil created by Timothy Leary in his open advocacy of psychedelics and his low regard for the encrustation he perceived in many institutions, generated enormous resistance in the academic world This caused SF State College to reverse their decision despite the fact that they had already printed a brochure describing the substantial potential that psychedelic drugs could offer, based upon a great deal of experience that had been gathered n the previous decade by knowledgeable investigators. 1966 Oct 6. Public use and the sale of LSD, DMT, Peyote and mescaline were prohibited. All scientific research was halted on the same day- with over 60 promising trials in progress, totally disregarding the exceptional positive results, and despite evidence of the limited medical risks and therapeutic potential of psychedelics. 1970 LSD, DMT, MDA, psylocibin & cannabis became labeled as Schedule 1 drugs under the Controlled Substance Act (CSA). (The CSA was Enacted by Congress to regulate the manufacture, distribution and use of certain drugs and other substances that have the potential for abuse or addiction. Psychedelics were placed in this category.) Penalties were established. They vary depending on the substance, quantity, and the defendant’s criminal history. 1971-86 The “War on Drugs” commences. Mandatory minimum sentencing enforced. Made drug use a criminal offense rather than a health issue. “Just Say No” and DARE Camps created fear and shame. For nearly 2 decades, research was halted. Researchers were stigmatized if they wanted to study psychedelics, and there was no government funding available. 1986. MAPS (Multidisciplinary Association for Psychedelic Studies). A Non-Profit 501c3 Public Benefit Corporation founded by attorney Rick Doblin, to end the prohibition against psychedelics both legally and culturally, fostering research, funding and resulting in persistent progress. It has had a huge influence and success in the FDA in 2019 declaring psychedelics as a breakthrough therapy. There is much to be said about this crucial organization that now sponsors conferences with 12,000 in attendance. For another time…. 1986 After years of being used as an adjunct to therapy by a small group of therapists, MDMA is deemed a Schedule 1 drug after it gained popularity in night clubs. No controlled studies after this time for decades. 1986-93- As Aids & Crack epidemics rage on, psilocybin use shifts to the Rave scene & festivals like Burning Man. 1993 National Harm Reduction Coalition forms in an effort to support vulnerable populations. 1996 Marijuana legalized in Oregon and Colorado 1998 Franz Vollenweider, the Swiss neuroscientist, discovers that LSD and psilocybin achieve their effects by binding with the brain’s 5-HT2A receptor 1989-1998 Rupert Sheldrake/Terence McKenna – talked of self -transformation during DMT travels. Rupert Sheldrake was a controversial biologist and author of more than 85 scientific papers and 9 books, and co-author of 6 books. Terence McKenna developed a taxonomy to analyze non- human intelligences. Was at Esalen Institute. McKenna said that “not until our primate ancestors began eating psychedelic plants did they begin to acquire human qualities. McKenna wrote “True Hallucinations”. He had fascinating ideas, a sense of humor & self- parody. As a youth he read Carl Jung’s Psychology and Alchemy. In 1972 he received a self-tailored degree in ecology, resource recovery and shamanism. He was an American ethnobotanist and mystic. 1946-2000 (died age 53) Said psychedelics were man’s salvation. Timothy Leary christened him the “Timothy Leary of the 90’s”. There were 3 authors to The Evolutionary Mind: Trialogues at the Edge of the Unthinkable- Ralph Abraham, Rupert Sheldrake and Terence McKenna. Their passion was to break out of paradigms that retard our evolution, and to explore new possibilities. They ventured where few have gone before, leading readers on an exciting journey of discovery. Ralph Abraham, PhD, chaos mathematician. The discussions in the Evolutionary Mind Trialogue focused on the evolution of the mind, the role of psychedelics, skepticism, the psychic powers of animals, the structure of time, the life of the heavens, the nature of God, and transformations of consciousness. “Written with startling insights and more wonder than we knew we had”. (Matthew Fox) In the past 10-15 years-several FDA approved clinical studies have indicated medical value for psilocybin assisted psychotherapy in the treatment of depression, anxiety and certain addictions- drug and alcohol & OCD, PTSD and quality of life/peace for cancer patients at the end of life. At present, assuming that the early clinical studies can be validated by larger studies, psylocibins are poised to make a very significant impact on treatments for otherwise ineffectual mental health. This research included clinical trials with MDMA- assisted treatment for PTSD, alcohol abuse, social anxiety, depression and addiction as well as the ability of psychedelics to catalyze spiritual or mystical experiences and inspire creativity. 1999 Dr. Roland Griffiths set up a research project at John Hopkins Univ to study the effects of psilocybin 2006 Griffiths publishes his LANDMARK paper showing that psilocybin can induce highly meaningful mystical experiences 2006 Research showed LSD and psilocybin could decrease cluster headaches in both intensity and frequency 2009 Dr Robin Carhart-Harris carried out the 1st clinical study of psi in the UK. This was also the 1st clinical study in 40 years in the UK. 2011 Charles Grob publishes research showing that psi decreases anxiety in patients with advanced cancer. Study shows that MDMA is a safe and effective treatment for PTSD 2014 Carhart-Harris showed in a study utilizing brain scans, that psi increases communication between areas of the brain that don’t normally communicate with each other. 2016 Carhart-Harris published brain scan images of how LSD affects the brain. 2018 Study illustrates that ayahuasca leads to significant decrease in depression 2019 The Imperial College of London launches the world’s 1st Center for Psilocybin Research. Some months later John Hopkins launces its own Center for Psychedelic and Consciousness Research Albert Marshall, indigenous leader, said we need “two eyed seeing”, referring to an integration of indigenous knowledge and sacred practices with the psychedelic plants used for healing and transformation, with the forthcoming medical approach. 2019 – FDA declares psychedelics as a BREAKTHROUGH THERAPY, based on the clinical trials from Compass Pathways and Usona Institute on psilocybin use for severe depression and major depressive disorders. The designation is meant to expediate the development and review of drugs that are intended to treat a serious condition. What was lacking in the 60’s-90’s was technology and hard scientific data. Today, we have MAPS submitting their Phase 3 Trial of MDMA ! Paul Stamets, 1955- current, prominent American mycologist, scientist, prolific researcher, advocate of medicinal fungi and myco-remediation, entrepreneur, started Fungi Perfecti with the goal of building the bridge between people and fungi. Since its inception in 1980, Fungi Perfecti has become synonymous with cutting-edge mycological research and solutions. His recent product- “Stamen’s Stacks” combines Lion’s Mane, niacin and psilocybin mushrooms to create a powerful healing tea with extraordinary anti-inflammatory effects, as stated by over 5000. Stage 1 studies begin in the near future. 2020 Nov 3. OR Ballot Measure 109 passes. “The Psilocybin Services Act”. (The Oregon Psilocybin Society, with founders Tom & Sheri Eckert, led the campaign to raise awareness about the safety and benefits of controlled psilocybin services.). It directs the OR Health Authority to regulate the manufacture, delivery, purchase and consumption of psilocybin mushrooms & psilocybin products to individuals 21 years of age and over. The Oregon Health Authority was given 2 years to establish the program and create regulations. A Psilocybin Advisory Board (OPAB) advises the OHA. The board has 14 members appointed by the governor. Clients are allowed to purchase, possess and consume psilocybin at a certified psilocybin service center and under the supervision of a certified psilocybin service facilitator after undergoing a preparatory session. OHA determines who is eligible to be licensed as a facilitator (training requires 160 hours), determines the qualifications, education, training and exams needed, and creates a “professional conduct” for facilitators. OHA sets psilocybin dosage standards and labeling and packaging rules. Measure 109 allowed cities and counties to place referendums on local ballots to prohibit or allow psilocybin product manufacturers or psilocybin service centers in unincorporated areas with their jurisdictions. 2020 Nov. Measure 110 made personal/non- commercial possession of a controlled substance, including psilocybin, no more than a class E violation with maximum fine of $100 or, one might, in lieu of a fine, completed a screening health assessment, as set forth in ORS 430.389 (Council to oversee and approve grants and funding to Behavioral Health Resource Networks & other entities to increase access to treatment and services), within 45 days of when the person receives the citation for the Class E violation. ) With completion of the assessment the court shall dismiss the citation. The failure to pay a fine on a Class E violation is not a basis for further penalties or for a term of incarceration (2021 c.2) 2021 Feb 1. Oregon Senate Bill 755-C codified and amended Ballot Measure 110, which decriminalize most unlawful possession of a controlled substance (PCS) offenses from a felony or misdemeanor to the new Class E violation. 2023 39 states now have legal access to marijuana. Polling shows that when people know of someone it has benefited, their opinion changes. Education is needed. There are currently 700+ ketamine clinics in the US. Over the next decade it is expected that there will be 6,000 Clinics. (There are 5-6 K hospice centers in the US). Legalization will help with dispelling demonization. Religious use is dramatically increasing, particularly with Ayahuasca. 2023 The 1st FDA approved group therapy Study is currently at the Veterans Administration in Portland, Oregon 2023 Nov. MAPS results of phase 2 and phase 3 study were delivered to the FDA. Phase 3 study on the use of psychedelics for major depression was published Oct 2023. Compass Pathways is starting Phase 3 study on treatment resistant depression. MAPS has an “agreement letter” from the FDA, so the FDA is legally bound to approve MDM if there is statistical significance, if there are no known safety problems, and if data has been gathered properly. However, it has been deemed that more studies are needed. This is a “New Drug Application”. There is a 6- month review time, as it would be a new “breakthrough” therapy. However, the clock stops when the FDA is finished with their questions. Then MAPS needs to respond, MAPS founder Rick Doblin felt that by May-June 2024 there should be FDA approval. However, FDA approval did not come. More studies are needed. THE FUTURE When FDA approval does come, the DEA will have 90 days to reschedule. It is not clear if the DEA would put it into Class 2 or 3, but they will have to reschedule it within 90 days, as Congress passed laws restricting them to 90 days- as in the past they’ve taken a notoriously long time to do it. Now, that’s not enough. The states need to reschedule as well. 50% of the states usually reschedule with the FDA changes. Others may need to go through their Public Health Board. California needs a new law. That is in the works now- a decriminalizing law, with a bill that says when the FDA approves psychedelics as a breakthrough therapy- MDMA will also be automatically approved. “There have been many promising series of discussions with insurance companies” Rick Doblin says. Insurance coverage is crucial. It doesn’t help a person if they get the drug for free, but they can’t afford the therapy. The FDA and DEA control the drugs, but they have no jurisdiction over psychotherapy. And all of the scientific studies have been based on Psychotherapy assisted psychedelic therapy. Doblin says “Peer support trainings and self-care training is needed so people can do this on their own”. Doblin has not seen any pushback from the pharmaceutical industry. “The drug war” has been largely discredited, so not seeing pushback. The value of helping people with PRSD is extremely large”. The value to the family is estimated to be 70K over the 1st 3 years. MAPS has a standardized treatment manual. It is in the Public Domain. It describes the therapeutic approach. With FDA approval, practitioners will need to be trained according to the protocol MAPS used in their Phase 3 trial. They want schools of psychiatry and psychotherapy as part of the core curriculum. But once the method is learned, there can be innovation- they won’t have to use MAPS “inner directed therapeutic method”. One can combine it with guided imagery. Current medical therapies are only addressing symptoms. Psychedelics address the core roots, and with neuroplasticity. New areas of research are mind-body, cognitive behavior conjoint therapy, IBS, fibromyalgia, cancer patients and their partners (study at Sanstone, Maryland) 2025. A lot of psychedelic studies will have gone through Phase 3 trials. Rick Doblin of MAPS stated we need a dual strategy: medical safety and a legal framework. He believes the issues with the FDA will be: · What therapies will be approved · How will we train 10,000 therapists · Combinations of different psychedelics, used in different ways · If/How group therapy can be as effective as individual therapy With research continuing into psychedelic substances and prohibitions gradually being relaxed, we will continue to see historic moments with psychedelics occurring in our lifetime (hopefully!).

Contact me for a free consultation Connect with Becca Parker, a trusted psilocybin facilitator, to schedule or inquire about facilitated experiences. Reach out to book psilocybin journey appointments or learn more about my supportive psychedelic journey services that help you along your path of healing and growth. Phone 503-819-3712 (Text OK) Email beccasuzanne2020@gmail.com Social Media Working in Southern Oregon and Throughout the State of Oregon Click this link to see Fees and Scholarship information. First Name Email Phone Best Time to Call Message Send Thanks for submitting! DISCLAIMER: When performing psilocybin preparation, journey facilitation, and integration I am NOT representing or utilizing my medical status. Stay informed on the latest breakthroughs and insights in psilocybin therapy! Join Becca's mailing list for exclusive updates, resources, and tools to support your journey. First name* Subscribe Email* I want to subscribe to your mailing list. "These substances open the door to what feels like an innate knowledge… Psilocybin shows us our true place in the cosmos and reminds us that we are more than mere passengers in our lives." ~Terence McKenna (Ethnobotanist and philosopher)

Client Intake Forms and Information Please review the following forms, provided by the Oregon Health Authority, to better understand information you may cover with a Becca, your licensed facilitator, during a preparation session. An individual accessing psilocybin services in Oregon is referred to as a client. Informed Consent - Updated 1.1.25 Client Bill of Rights - Updated 1.1.25 Client Information Form - Updated 1.1.25 Client Transportation Plan - Updated 12.27.22 Client Safety and Support Plan - Updated 1.1.25 Client Medication and Medical/Assistive Device Form - Updated 1.1.25 Interpreter or Client Support Person Plan - Updated 1.1.25 303 Client Data Form - Updated 1.1.25 Authorization to Disclose Personal Identifiable Information - Updated 1.1.25 Notice and Opt-Out of Disclosure of De-Identified Data - Updated 1.1.25 Client Consent for Other Individuals to Be Present During an Administration Session - Updated 1.1.25 Client Consent for Use of Supportive Touch During Administration Session - Updated 1.1.25 Psilocybin Product and End of Session Form - Updated 1.1.25 Client Consent for Video and Audio Recording of Individual Administration Session - Updated 1.1.25 Client Consent for Video and Audio Recording of Group Administration Session - Updated 1.1.25

Explore psilocybin therapy services, which include facilitated preparation, psilocybin journey and psychedelic integration support. My tailored approach provides guided psychedelic journeys and individualized coaching, prioritizing safe therapeutic practices for every participant. PREPARATION Preparatory sessions for a psilocybin journey are important for several reasons: Mental preparation is key; enter with a calm, open mind, free from major stresses. Abstain from alcohol or substances for several days before the journey. Also abstain from action packed and violent movies the night before and eat lightly 1-2 days before the journey experience. In Indigenous communities individuals often fast for 2 days prior to a journey. ( This can also alleviate physical symptoms that some may have, such as a mild headache or nausea. ) * Setting Intentions: They help individuals clarify their intentions, which can focus the experience and provide a framework for insights. *Building Trust: Establishing a rapport with your facilitator fosters a sense of safety and trust, which is crucial for a supportive environment during the journey. * Understanding Expectations: Preparatory sessions provide information about what to expect, 30 pages of required paperwork from the Oregon Health Authority ( the overarching authority which regulates psilocybin services in the state) which insures informed consent, helping individuals manage anxiety and prepare mentally for the experience. Services to you would include an average of 6 hours, broken into 2 hour segments- in person, on Zoom or by phone, whichever is most comfortable to you. We take the time it takes until you feel ready. * Addressing Concerns: You can discuss fears or concerns, allowing for a more open and relaxed mindset going into the journey. * Personalization: Preparatory sessions allow facilitators to tailor the experience based on your needs, ensuring a more relevant and beneficial journey. * Integration Planning: Preparation can also lay the groundwork for post-journey integration, discussing how to process and apply insights gained during the experience. Overall, preparation enhances safety, efficacy, and the potential for positive outcomes in the psilocybin journey. THE JOURNEY A psilocybin journey, often referred to as a “trip,” is a profound experience that varies widely depending on the person, dosage, mindset, and setting. Here’s a general description: 1. Onset (20-60 minutes): After consuming psilocybin mushrooms, most people feel effects within 20 to 60 minutes. Many start with a sense of mild anticipation or excitement, sometimes accompanied by physical sensations like warmth or tingling. There can be mild nausea or headache. Some may be cold, others hot with profuse sweating. So bring an extra pair of clothes. This stage can bring heightened awareness of one’s surroundings, with colors appearing brighter, sounds more immersive, and an overall sense of “shifting” from normal perception. 2. Peak (2-4 hours): The peak is the most intense part of the journey. Visuals may become more pronounced, with colors and patterns appearing to move, change, or “breathe.” Closed-eye visuals can also become vivid, often displaying geometric shapes, mandalas, or scenes that feel profound or symbolic. With focus one can move beyond the visuals to focus on the intentions & purpose for the journey. During this phase, people often experience deep introspection and feel a connection to nature, the universe, or their inner selves. Emotions are often amplified, and thoughts can be more fluid and nonlinear, with "downloads" of information & understanding happening instantaneously. Some describe this as a moment of “ego dissolution,” where they feel a release from their usual sense of self and connected to something greater. This can be both blissful and challenging, depending on the individual. 3. Plateau (1-2 hours): After the peak, things begin to stabilize. Visuals may soften, but the insights and emotional waves remain strong. Many describe this as a phase of integration, where they reflect on the peak experience, gaining insights or coming to terms with feelings or thoughts. 4. Comedown (1-2 hours): As the effects continue to fade, the journey usually transitions into a more relaxed state. Some people feel physically tired, exhausted or energized but mentally refreshed, with a lingering & strong sense of peace and connection. Reflecting on the experience can bring a “glow” that lasts for hours or even days. Many feel an afterglow of clarity, emotional release, or a renewed sense of perspective on life. Preparation enhances safety, efficacy, and the potential for positive outcomes in the psilocybin journey. It requires mindfulness, intention, and creating a safe, supportive environment. Set a clear intention: 'why are you taking this journey, and what do you hope to explore or gain?' Choose a quiet, comfortable setting, free from distractions. Have a trusted guide who can provide reassurance if needed. Be sure there is water available and bring any favorite music or comfort items with you. Mental preparation is key; enter with a calm, open mind, free from major stresses. Avoid alcohol or substances, action packed and violent movies the night before and eat lightly 1-2 A psilocybin journey, often referred to as a “trip,” is a profound experience that varies widely depending on the person, dosage, mindset, and setting. Here’s a general description: 1. Onset (20-60 minutes): After consuming psilocybin mushrooms, most people feel effects within 20 to 60 minutes. Many start with a sense of mild anticipation or excitement, sometimes accompanied by physical sensations like warmth or tingling. There can be mild nausea or headache. Some may be cold, others hot with profuse sweating. So bring an extra pair of clothes. This stage can bring heightened awareness of one’s surroundings, with colors appearing brighter, sounds more immersive, and an overall sense of “shifting” from normal perception. Have a trusted guide who can provide reassurance if needed. 2. Peak (2-4 hours): The peak is the most intense part of the journey. Visuals may become more pronounced, with colors and patterns appearing to move, change, or “breathe.” Closed-eye visuals can also become vivid, often displaying geometric shapes, mandalas, or scenes that feel profound or symbolic. With focus one can move beyond the visuals to focus on the intentions & purpose for the journey. During this phase, people often experience deep introspection and feel a connection to nature, the universe, or their inner selves. Emotions are often amplified, and thoughts can be more fluid and nonlinear, with "downloads" of information & understanding happening instantaneously. Some describe this as a moment of “ego dissolution,” where they feel a release from their usual sense of self and connected to something greater. This can be both blissful and challenging, depending on the individual. 3. Plateau (1-2 hours): After the peak, things begin to stabilize. Visuals may soften, but the insights and emotional waves remain strong. Many describe this as a phase of integration, where they reflect on the peak experience, gaining insights or coming to terms with feelings or thoughts. 4. Comedown (1-2 hours): As the effects continue to fade, the journey usually transitions into a more relaxed state. Some people feel physically tired, exhausted or energized but mentally refreshed, with a lingering & strong sense of peace and connection. Reflecting on the experience can bring a “glow” that lasts for hours, days or even months. Many feel an afterglow of clarity, emotional release, or a renewed sense of perspective on life. INTEGRATION Optimizing the integration of a psilocybin journey is key to maximizing its insights and transformative potential. Here’s a step-by-step guide that can help: 1. Immediate Aftercare (Day of Journey) Rest and Reflect: Right after the experience, rest and give yourself time to process. Take time to sit quietly, allowing your mind and body to recalibrate. Hydration and Nutrition: Rehydrate with water or herbal teas, and eat something nourishing to ground yourself. 1. Journaling: Write down immediate impressions, emotions, and key moments from the journey. Capturing raw thoughts can provide context for later reflection. 2. Set Intentions for Integration (Days Following Journey) Define Key Themes: Think about major insights or themes from the journey. Write down any realizations or messages that felt important. Set Actionable Goals: Break down themes into small, actionable changes that align with your values. For example, if the journey emphasized self-compassion, set a goal to incorporate self-care practices. 3. Supportive Practices (First Week) Meditation: Daily meditation can help integrate insights by keeping you present and open to emotional processing. Breathwork or Yoga: Engaging in gentle movement or deep breathing exercises helps release any stored emotions and can ground insights into the body. Nature Time: Spending time in nature can be deeply grounding and is often beneficial for reflecting on the journey’s themes. 4. Community and Support (Ongoing) Therapeutic Support: Consider working with a therapist trained in psychedelic integration if the journey brought up unresolved trauma or deep psychological issues. Integration Circles: Join a local or online community of people who have had similar experiences, allowing you to discuss and process openly. Creative Expression: Expressing your experience through art, writing, music, theatre or other creative outlets can be very healing. 5. Sustaining Changes (Weeks to Months) Revisit Your Journal: Periodically reread your journal entries, looking for recurring themes or patterns. Utilize archetypes for progress or remaining needed work. Incorporate Lessons into Daily Life: Gradually implement the lessons learned into your day-to-day routines. Small, mindful shifts often have the most sustainable impact. Be Patient: Integration is an ongoing journey. Allow yourself time, as profound changes often emerge gradually. 6. Evaluate and Adjust (Every Few Months) Reflect on Growth: Reassess the journey’s impact on your life. Consider what has shifted and where you still feel called to grow. Set New Intentions: Use each checkpoint to set new, meaningful intentions or renew previous ones, adapting as needed. “Even if you are on the right track, you’ll get run over if you just sit there.” ― Will Rogers

Veteran's Pathway to Peace Project MATERIALS FOR PAGE https://www.ptsd.va.gov/professional/assessment/adult-sr/ptsd-checklist.asp It is a Symptom Rating Scale for PTSD developed by the Veterans Administration. What would be even better is to have the PCL-5 scale right on the website.

Get answers to your most pressing psilocybin journey FAQs on our dedicated page. We address common psilocybin concerns, preparation for a psilocybin journey, and safety considerations in psilocybin sessions, ensuring you feel informed and prepared for your experience. Fees

Comprehensive Facilitation for Transformative & Healing Psilocybin Journeys Discover evolutionary psilocybin journey facilitation designed to guide you safely through a transformative psilocybin experience. As a Psilocybin Journey Facilitator, I offer preparatory coaching, journey facilitation and psychedelic integration coaching that supports safe psilocybin sessions for consciousness exploration and transformational healing. "I do know of a therapist; it's called a mushroom. Ask them for help" ~Bess Williams Hi: My name is Becca Parker, Welcome in! I am a Certified Psilocybin Journey Facilitator, based in the heart of the destination vacation site of Ashland, in Southern Oregon . I am here to guide you on a safe, insightful, and transformative journey with psilocybin, whether you’re seeking personal healing, spiritual growth, or deep self-exploration. Psilocybin-assisted therapy addresses spiritual exploration and well-being, personal growth, creativity, mental health improvement and recovery- including trauma/PTSD, depression, anxiety, addictions & end-of-life harmony and closure. Compassionate, adept, facilitation ensures that each experience is tailored to your needs, offering you the support and integration tools necessary for meaningful results. Allow me to walk with you on this path toward clarity, connection, and well-being. With a 50 year background in healing as a nurse practitioner, certified nurse midwife, RN and nutritionist, as well as being a 50 year practitioner of meditation and yoga, I am dedicated to providing a safe haven and supportive environment for you to embark on a transformative life-changing and healing experience. More About Me "With the little ones (psilocybin mushrooms), we travel, we heal, we see the unseen. We learn to listen, to the Earth, to our hearts. They heal us by showing us who we are and who we are meant to be.” ~Sage Ritual Words from Mazatec Psilocybin Ceremony

References and Referrals Welcome to our References and Referrals page. Here, you will find a curated collection of trusted professionals, including doctors, former clients, and experts within the psilocybin industry. These individuals and organizations have played an integral role in supporting the transformative journey of healing and growth through psilocybin therapy. Whether you're seeking medical guidance, client testimonials, or insights from experienced facilitators, this page connects you with a network of knowledgeable and compassionate professionals committed to safe and effective psychedelic experiences. Feel free to explore the references below to learn more about the impact of psilocybin and the trusted individuals who make these journeys possible. "I have had the honor of knowing and working alongside Becca Parker FNP for over 15 years, both as a colleague practicing holistic health and as a friend. As a medical doctor, I've witnessed her unwavering dedication to her client's well-being and exceptional expertise in integrated medicine. Becca's professionalism is unmatched, and her extensive medical background as a Family Nurse Practitioner, Nurse Midwife, and Nutritionist adds a level of expertise and unique skill set to her practice that is truly special. What sets Becca apart is her character. Her kindness, compassion, empathy and genuine desire to assit clients on their healing journey creates a nurturing and safe and supportive environment. Her integrity, compassion and dedication to her craft is truly commendable. Becca's additional training as a certified psilocybin facilitator brings an additional level of skills to help support clients who are seeking transformative psilocybin experience. I wholeheartedly recommend Becca to those seeking a psilocybin journey. " — Dr. Whitacre